CRISPR Therapeutics AG
NASDAQCRISPR Therapeutics enters mid-May with one of the most heavily shorted profiles in the gene-editing space — yet the lending market has loosened meaningfully from its April extremes, creating a tension at the heart of the current setup. Short interest stands at 23.4% of the free float, with roughly 22.3 million shares borrowed as of May 12. That is a substantial position — placing…
Snapshot as of 22 Jun 2026
CRISPR Therapeutics enters mid-May with one of the most heavily shorted profiles in the gene-editing space — yet the lending market has loosened meaningfully from its April extremes, creating a tension at the heart of…
CRSP heads into its May 11 earnings report carrying one of the most crowded short positions in biotech — and fresh evidence that options traders turned meaningfully more defensive this week. The options signal is the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CRSP — free to start on ORTEX.
Sign up for free →Open CRSP on ORTEX